Literature DB >> 24112412

Indocyanine green plasma disappearance rate: a new tool for the classification of paediatric patients with acute liver failure.

Jesús Quintero1, Mar Miserachs, Juan Ortega, Javier Bueno, Cristina Dopazo, Itxarone Bilbao, Lluis Castells, Ramon Charco.   

Abstract

BACKGROUND & AIMS: Pediatric acute liver failure is a rare disorder which results in death or the need for liver transplantation in 25-50% of cases. The adults scores are unable to predict survival without liver transplantation of pediatric patients. The present study assessed the use the of indocyanine green plasma disappearance rate as a tool to predict the evolution of pediatric patients with acute liver failure. PATIENTS AND METHODS: All patients met the criteria of acute liver failure according to the Pediatric Acute Liver Failure Study Group. King's College, Clichy's criteria and ICG-PDR were obtained on admission or when acute liver failure was diagnosed and repeated every 12-24 hours, respectively.
RESULTS: Thirteen out of 48 patients suffered an irreversible liver damage. Seven of them underwent a liver transplantation and 6 died on the waiting. A total of 154 ICG-PDR measurements were taken during the study (Median 12.4 %/min, r:6.2 - 26.3). The ICG-PDR was significantly lower in patients who suffered irreversible liver damage compared with those who survived without liver transplantation (median ICG-PDR 4.1 %/min; r:4.0 - 5.7 vs median ICG-PDR 20.3 %/min; r: 9.1 - 30.1; respectively. P < 0.001). Using a ROC curve the cutoff of ICG-PDR for assessing the need for liver transplantation was set at 5.9 %/min (sensitivity 92.3%, specificity 97.1%). Sensitivity, specificity, PPV, NPV and DA for ICG-PDR were higher than the King's College and Clichy's criteria.
CONCLUSIONS: ICG-PDR is a powerful tool that would improve the categorization of patients with pediatric acute liver failure.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  acute liver failure; liver transplantation; paediatric liver diseases

Mesh:

Substances:

Year:  2013        PMID: 24112412     DOI: 10.1111/liv.12298

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  6 in total

Review 1.  Assessment of liver perfusion and function by indocyanine green in the perioperative setting and in critically ill patients.

Authors:  Samir G Sakka
Journal:  J Clin Monit Comput       Date:  2017-10-16       Impact factor: 2.502

2.  Fluorescence Imaging Using Indocyanine Green Dye in the Pediatric Population.

Authors:  Shabana Zainab Shafy; Mohammed Hakim; Susan Lynch; Lian Chen; Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2020

3.  Perioperative Non-Invasive Indocyanine Green-Clearance Testing to Predict Postoperative Outcome after Liver Resection.

Authors:  Stefanie Haegele; Silvia Reiter; David Wanek; Florian Offensperger; David Pereyra; Stefan Stremitzer; Edith Fleischmann; Christine Brostjan; Thomas Gruenberger; Patrick Starlinger
Journal:  PLoS One       Date:  2016-11-03       Impact factor: 3.240

4.  Prognostic Impact of Indocyanine Green Plasma Disappearance Rate in Hepatocellular Carcinoma Patients after Radiofrequency Ablation: A Prognostic Nomogram Study.

Authors:  Motoi Azumi; Takeshi Suda; Shuji Terai; Kouhei Akazawa
Journal:  Intern Med       Date:  2017-05-01       Impact factor: 1.271

5.  The Advantages of Indocyanine Green Fluorescence Imaging in Detecting and Treating Pediatric Hepatoblastoma: A Preliminary Experience.

Authors:  Yu Jeong Cho; Jung-Man Namgoong; Hyun Hee Kwon; Yong Jae Kwon; Dae Yeon Kim; Seong Chul Kim
Journal:  Front Pediatr       Date:  2021-02-26       Impact factor: 3.418

6.  Hepatoprotective potential of a novel quinazoline derivative in thioacetamide-induced liver toxicity.

Authors:  Suzy Salama; Chin Siang Kue; Haryanti Mohamad; Fatima Omer; Mohamed Yousif Ibrahim; Mahmood Abdulla; Hapipah Ali; Abdalbasit Mariod; Soher Nagi Jayash
Journal:  Front Pharmacol       Date:  2022-09-20       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.